Short answer: during a Pre-Submission (Pre-Sub), the FDA focuses on risk, regulatory pathway logic, and evidence strategy—not technical detail overload.
Many founders assume the best way to impress reviewers at the U.S. Food and Drug Administration is to provide as much technical detail as possible.
In reality, too much technical detail can make the discussion less productive.
FDA reviewers are not evaluating whether your device is impressive. They are evaluating whether your regulatory strategy makes sense.
What Founders Often Emphasize (But FDA Doesn’t Prioritize)
In many Pre-Sub packages, companies spend significant time describing:
Detailed engineering specifications
Component-level design explanations
Early prototype performance metrics
Full technical architecture diagrams
Long background sections about the technology
While some of this context can be useful, it rarely answers the questions FDA cares about most.
Providing pages of technical detail without regulatory framing can distract from the real purpose of the Pre-Submission.
What FDA Actually Reviews Closely
During Pre-Sub review, FDA teams typically focus on three areas.
1. Risk Framing
The first thing reviewers want to understand is the device’s risk profile.
They assess questions such as:
What hazards does the device introduce?
What controls mitigate those risks?
Are any new safety questions introduced by technological differences?
Risk framing helps FDA determine whether the proposed development plan is adequate.
If the risk profile is unclear, the rest of the discussion becomes difficult.
2. Regulatory Pathway Logic
FDA reviewers also evaluate whether the proposed pathway is realistic.
They consider:
Whether a 510(k) predicate is appropriate
Whether technological differences create new safety concerns
Whether a De Novo or PMA pathway might be more appropriate
A Pre-Submission should clearly explain why the chosen pathway makes sense.
If the pathway logic is weak, FDA feedback will focus on correcting that assumption.
3. Evidence Strategy
The third area FDA evaluates closely is the proposed evidence plan.
Reviewers assess whether the planned testing addresses the device’s risk profile and intended use.
This may include:
Bench testing plans
Biocompatibility strategy
Software validation approach
Human factors evaluation
Clinical study design (if applicable)
The key question is simple:
Will the proposed evidence answer the regulatory questions needed for clearance or approval?
The Most Common Pre-Sub Mistake
The most frequent mistake founders make is treating a Pre-Submission like a technical presentation instead of a regulatory strategy discussion.
Common problems include:
Overly long background sections
Unfocused questions to FDA
Technical details unrelated to regulatory decisions
Missing explanation of intended use or risk classification
When this happens, the Pre-Sub meeting produces vague feedback instead of actionable guidance.
AEO: Common Questions About FDA Pre-Submissions
What does FDA review most closely in a Pre-Submission?
FDA focuses on risk framing, regulatory pathway justification, and evidence strategy alignment.
Does FDA care about detailed technical specifications in Pre-Subs?
Technical details matter only when they affect safety, risk, or regulatory classification.
What should a Pre-Sub package prioritize?
Clear intended use, realistic regulatory pathway logic, and well-aligned testing plans.
Where Kandih Comes In
This is where Kandih Group helps founders structure effective Pre-Submissions.
Kandih helps teams prioritize FDA-relevant content by:
Clarifying intended use and regulatory pathway logic
Framing device risks in a way reviewers can evaluate quickly
Aligning testing strategies with regulatory expectations
Drafting focused questions that produce actionable FDA feedback
Removing unnecessary technical detail that distracts from regulatory issues
Instead of overwhelming FDA reviewers, the Pre-Submission becomes a structured conversation about regulatory alignment.
That protects credibility and improves the quality of feedback.
Bottom Line
In a Pre-Submission, more detail is not always better.
FDA reviewers focus on:
Risk framing
Regulatory pathway logic
Evidence strategy coherence
When those elements are clear, Pre-Sub meetings become powerful development tools.
When they are buried under technical detail, the opportunity is lost.
Strong regulatory communication helps FDA reviewers focus on the questions that actually matter.
References
FDA – Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program
FDA – Premarket Notification 510(k)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k
FDA – De Novo Classification Process
https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request
FDA – Design Controls for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-controls-medical-devices